November 13, 2023
StemRIM Inc.

StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023

Osaka, Japan, November 13, 2023 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that extension the collaborative research period of the tripartite joint research agreement, updated on January 24, 2023, with Shiseido Co., Ltd. (TSE: 4911, Chairman and CEO: Masahiko Uotani, “Shiseido”) and Osaka University, a national university corporation, Graduate School of Medicine (“Osaka University”).

Our collaborative research, conducted among our company, Shiseido, and Osaka University, focuses on elucidating the aging mechanisms of skin stem cells with a particular emphasis on anti-aging of the skin. The aim is to create new pharmaceuticals, cosmetics, and related products based on data obtained from understanding the aging mechanisms. Through the ongoing collaborative research, we have achieved certain research results regarding changes in stem cells related to skin aging. Recognizing the need for further analysis, we have extended the research period to continue advancing research towards the creation of new pharmaceuticals and cosmetics.

Furthermore, we would like to emphasize that the specific details of this collaborative research agreement are considered confidential as per the contracts with Shiseido and Osaka University. The impact on the financial performance for the fiscal year ending July 31, 2024, is nothing. Nevertheless, we believe it contributes to the medium to long-term improvement of our overall performance.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis

of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
Twitter: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)